Jiansu Hengrui Medicine and LSK BioPharma were approved to begin US trials of their PD-1-based combination therapy as a first-line treatment for advanced hepatocellular carcinoma. The combination pairs Hengrui's anti-PD-1 mAb (currently under NDA review in China for classic Hodgkin's Lymphoma) with LSKB's rivoceranib, a selective VEGFR-2 inhibitor commonly known as apatinib. The combination produced an objective response rate of 50% and disease control rate of 85.7% in a China Phase I trial. More details....
Stock Symbol: (SHA: 600276)
Share this with colleagues:
Original Article: Hengrui and LSK Approved to Start US Trial of PD-1/VEGF-2 Combination